While the broader sector struggled, specific corporate developments offered pockets of activity. Austin-based 4E Therapeutics confirmed its acquisition by Eli Lilly. The neuroscience firm specializes in developing chronic pain treatments, focusing on compounds designed to provide relief without the central nervous system side effects common in existing therapies.

Separately, market sentiment toward UnitedHealth saw a boost from analysts at Leerink Partners. The firm raised its price target for the company to $462 from $400, pointing to improved margin forecasts for the Optum Health unit. This division remains a cornerstone of the company’s portfolio, currently providing medical care to millions of patients nationwide.